General Information of Drug (ID: DMIMPDL)

Drug Name
PCI-34051 Drug Info
Synonyms
PCI-34259; PCI-34260; PCI-40505; PCI-43744; PCI-45159; PCI-47634; PCI-48000; PCI-48001; PCI-48002; PCI-48003; PCI-48004; PCI-48006; PCI-48007; PCI-48008; PCI-48009; PCI-48010; PCI-48011; PCI-48012; PCI-48013; PCI-48018; PCI-48036; PCI-48039; HDAC 8 inhibitors (cancer/inflammation); HDAC 8 inhibitors (cancer/inflammation), Pharmacyclics
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
PubChem CID
24753719
ChEBI ID
CHEBI:94192
CAS Number
CAS 950762-95-5
TTD Drug ID
DMIMPDL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NBM-BMX DM5OWXA Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 8 (HDAC8) TTT6LFV HDAC8_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2619).
2 Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
3 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.